Neogap raises SEK 83 million for a clinical phase I/II cancer study
The Swedish biotechnology company Neogap Therapeutics announces that the company has raised SEK 54 million in a new share issue and has also been granted an additional SEK 29 million in innovation funding from the EU. The total capital injection will be allocated to the company's ongoing clinical phase I/II study of patients with colorectal cancer and preparations for the subsequent study.Neogap Therapeutics, a company developing cell therapy for personalised cancer treatment, has strengthened its financial position through a new share issue of SEK 54 million, before issue costs, with the